Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Arimidex in McCune Albright Syndrome
This study is currently recruiting patients.
Sponsored by: | AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
Purpose
The primary objective of this study is to evaluate the safety and efficacy of anastrozole 1 mg given once daily in subjects with McCune-Albright Syndrome.
Condition | Treatment or Intervention | Phase |
---|---|---|
McCune-Albright Syndrome |
Drug: Arimidex 1 mg |
Phase II |
MedlinePlus related topics: Bone Diseases
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: An Open-label Study Evaluating the Safety and Efficacy of Anastrozole™ (ARIMIDEX) in the Treatment of Precocious Puberty in girls with McCune-Albright Syndrome
Eligibility
Ages Eligible for Study: up to 10 Years, Genders Eligible for Study: Female
Criteria
Inclusion Criteria:
Exclusion Criteria: Any one of the following is regarded as a criterion for exclusion from the study:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |